Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on November 13, 2017, primarily announcing its third-quarter 2017 financial results and significant progress in its clinical development program for BGB-3111, a Bruton's Tyrosine Kinase (BTK) inhibitor. From a financial perspective, the filing references the press release detailing Q3 2017 results, which investors would look to for revenue, expenses, and net income/loss. From a strategic standpoint, the company highlighted the initiation of two new global pivotal clinical trials for BGB-3111: a Phase 3 trial in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and a pivotal Phase 2 trial in combination with GAZYVA® for relapsed or refractory follicular lymphoma. Additionally, patient enrollment was completed for a pivotal trial of BGB-3111 in China for mantle cell lymphoma. These developments underscore the company's commitment to advancing its lead oncology candidate through late-stage development across multiple indications.
Key Highlights
- 1Announcement of third quarter and nine months ended September 30, 2017 financial results.
- 2Initiation of a global Phase 3 clinical trial for BGB-3111 in previously untreated CLL/SLL patients.
- 3Initiation of a global pivotal Phase 2 clinical trial for BGB-3111 in combination with GAZYVA® for relapsed/refractory follicular lymphoma patients.
- 4Completion of patient enrollment in a pivotal trial for BGB-3111 in China for mantle cell lymphoma patients.
- 5BGB-3111 is an investigational Bruton's Tyrosine Kinase (BTK) inhibitor.
- 6The information provided is furnished and not deemed "filed" under Section 18 of the Exchange Act.